Parameter
| Biomarker | Leucine-rich alpha-2-glycoprotein 1 + TIMP metallopeptidase inhibitor 1 + CA19-9 | Full name | LRG1+TIMP1+CA19-9 (combined panel) | Molecular Type | Protein combinationsProtein combinations |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Early diagnosis | ||
| Disease | Pancreatic Cancer | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Serum (mass spectrometry, immunoassay) | ||
| Pathobiological Mechanisms | LRG1 involved in tumor matrix remodeling, TIMP1 regulating the activity of matrix metalloproteinases, and CA19-9 can cover different pathological process of molecular changes | ||||
| Clinical Availability Status | Clinical research phase: It has been validated in multi-center studies and is significantly superior to single markers | ||||
| Notes and Dynamics | Sensitivity and specificity to the diagnosis of early PDAC are higher than used alone CA19-9, is potential joint diagnosis scheme | ||||